

Supplementary Material

PBT2 Rapidly Improves Cognition in Alzheimer's Disease: Additional Phase II Analyses

Noel G. Faux^a, Craig W. Ritchie^b, Adam Gunn^a, Alan Rembach^{a,c}, Andrew Tsatsanis^a, Justin Bedo^d, John Harrison^e, Lars Lannfelt^f, Kaj Blennow^g, Henrik Zetterberg^g, Martin Ingelsson^f, Colin L. Masters^a, Rudolph E. Tanzi^h, Jeffrey L. Cummingsⁱ, Caroline M. Herd^j and Ashley I. Bush^{a,k,*}

^a*Mental Health Research Institute, The University of Melbourne, Parkville, VIC, Australia*

^b*Department of Psychological Medicine, Imperial College London, London, UK*

^c*CSIRO Parkville, VIC, Australia*

^d*Victorian Research Laboratory, National ICT of Australia (NICTA)*

^e*CogState Ltd, Warminster, UK*

^f*Department of Public Health / Geriatrics, Uppsala University Hospital, Uppsala, Sweden*

^g*Clinical Neurochemistry Laboratory, Sahlgren's University Hospital, Mölndal, Sweden*

^h*Genetics and Aging Research Unit, Massachusetts General Hospital, Boston, MA, USA*

ⁱ*Mary S. Easton Center for Alzheimer's Disease Research at UCLA, Los Angeles, CA, USA*

^j*Prana Biotechnology Ltd, Parkville, Victoria, Australia*

^k*Department of Pathology, The University of Melbourne, Parkville, VIC, Australia*

*Correspondence to: Professor Ashley I. Bush, The Mental Health Research Institute, 155 Oak Street, Parkville, VIC 3052, Australia.
Tel.: +61 3 9389 2962; Fax: +61 3 9387 5061; E-mail: a.bush@mhri.edu.au.

Supplementary Table 1

Means, standard deviations (sd), minimums (min) and maximum (max) of the pretreatment cohort for free copper and metalloenzymes

	Baseline			
	n	mean	sd	min max
Total amine oxidase activity (U/L)	74	97.8	25.6	57.6 195.8
Ceruloplasmin protein (mg/L)	74	312.3	95.2	100.5 618.3
Ceruloplasmin specific activity (U/mg)	74	0.319	0.100	0.160 0.830
Ceruloplasmin oxidase activity (U/L)	74	94.1	24.6	55.9 187.6
Erythrocyte SOD1 protein concentration (mg/ml)	59	0.172	0.077	0.080 0.410
SOD1 specific activity (U/mg)	59	3655.9	1310.5	1461.6 7087.5
SOD1 activity (U/ml)	59	553.5	127.8	319.0 858.8
Free copper (μmol)	72	1.39	0.35	0.82 2.37

Supplementary Table 2

Means, standard deviations (sd), minimums (min) and maximum (max) at week 12 (study end), for each of the three PBT2 dose groups, for free copper and metalloenzymes

	week 12 Placebo				week 12 PBT2 50mg				week 12 PBT2 250mg			
	n	mean	sd	min max	n	mean	sd	min max	n	mean	sd	min max
Total amine oxidase activity (U/L)	28	99.0	24.8	61.3 155.8	19	105.9	40.5	71.5 254.6	27	105.3	24.3	71.3 171.4
Ceruloplasmin protein (mg/L)	28	319.4	97.6	178.2 521.4	19	323.8	92.9	154.0 521.2	27	285.1	80.3	136.7 490.2
Ceruloplasmin specific activity (U/mg)	28	0.315	0.102	0.190 0.600	19	0.324	0.091	0.190 0.470	27	0.376	0.122	0.190 0.830
Ceruloplasmin oxidase activity (U/L)	28	95.1	24.2	58.7 151.5	19	101.7	39.3	68.7 245.9	27	101.2	23.4	69.5 165.1
Erythrocyte SOD1 protein conc, (mg/ml)	22	0.169	0.095	0.080 0.440	15	0.139	0.055	0.1 0.230	26	0.160	0.064	0.090 0.300
SOD1 specific activity (U/mg)	22	4004.6	1806.9	1409.4 7661.4	15	4254.0	1470.5	2480.9 6875.5	26	3894.0	1475.9	1812.9 7138.1
SOD1 activity (U/ml)	22	551.4	137.9	298.0 794.1	15	549.0	174.0	293.5 940.1	26	556.1	140.6	312.8 838.1
Free copper (μmol)	28	1.22	0.29	0.80 1.98	19	1.28	0.44	0.77 2.30	27	1.22	0.43	0.59 2.30